CPC C07K 16/468 (2013.01) [C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] | 7 Claims |
1. A composition comprising an anti-CD3 antibody binding domain, said anti-CD3 binding domain comprising:
a) a variable light domain comprising a vlCDR1 having the sequence GSSTGAVTTSNYAN (SEQ ID NO: 15), a vlCDR2 having the sequence GTNKRAP (SEQ ID NO: 16), and a vlCDR3 having the sequence ALWYSNHWV (SEQ ID NO: 17); and
b) a variable heavy domain comprising a vhCDR1 having the sequence TYAMN (SEQ ID NO: 11), a vhCDR2 having the sequence RIRSKANNYATYYADSVKG (SEQ ID NO: 12) and a vhCDR3 having the sequence HGNFGDSYVSWFAY (SEQ ID NO: 13).
|